sur GENFIT (EPA:GNFT)
GENFIT receives €26.5 million following a key milestone in Italy
GENFIT, a biopharmaceutical company listed on Nasdaq and Euronext, announced that it will receive a milestone payment of €26.5 million. This payment follows Ipsen's pricing and reimbursement approval for Iqirvo® in Italy for the treatment of primary biliary cholangitis. This decision is part of a licensing and collaboration agreement with Ipsen, validated in three major European markets.
Iqirvo® had already received these approvals in the UK and Germany. This payment will contribute to the development of drugs for acute on-chronic liver failure (ACLF) and other serious diseases. Milestone payments are excluded from the royalty-sharing agreement with HCRx.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENFIT